A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
NCT02841267
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
19
Enrollment
OTHER
Sponsor class
Conditions
LGMD2I
Interventions
DRUG:
PF 06252616
Sponsor
Kathryn Wagner
Collaborators
[object Object]